Themis Secures €40M in Series D Financing
Summary
MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) and Adjuvant Capital, as well as current investors Global Health Investment Fund, aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences, also participated. Concurrent with the financing, Dr. Walter Stockinger, Managing Partner at Hadean Ventures, will join Themis’ Supervisory Board. Led by Erich Tauber, MD, CEO, Themis is developing immunomodulation therapies for infectious diseases and cancer. Initially focused on preventing infectious diseases, Themis has demonstrated the potential of its versatile platform through the completion of Phase 2 and near-term entry into Phase 3 clinical development for a vaccine against Chikungunya, a debilitating disease with global outbreak potential. The company’s other vaccine programs include those for Zika and Lassa Fever, which are currently being studied in Phase 1 clinical trials, and for Respiratory Syncytial Virus (RSV), Cytomegalovirus (CMV), Norovirus and Middle East Respiratory Syndrome (MERS), which are in pre-clinical studies.